Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
A new study published in The BMJ has found that adults with type 2 diabetes who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), may face a higher risk of developing non-scarring hair loss (alopecia) compared with patients taking other commonly prescribed diabetes medicines
A body composition substudy of the Phase 2 diabetes trial, published in The Lancet Diabetes & Endocrinology in 2025, used DXA scans to measure changes in fat and lean mass in 189 participants
Semaglutide in Obesity and Type 2 Diabetes Management: A Systematic Review of Clinical Outcomes
The same drug goes for as much as $349 a month in the US without insurance (where patents dont expire until 2032)
Its a prescription medication for type 2 diabetics to manage blood glucose levels
